GoutQuestions = [
    {
        "question": "Evidence level ___ is supported by _____ randomized clinical trials or meta analysis",
        "answer": "A, multiple",
        "type": "text"
    },
    {
        "question": "Evidence level ___ is derived from a ____ randomized trial or non randomized studies",
        "answer": "B, single",
        "type": "text"
    },
    {
        "question": "Evidence level ___ is consensus opinion of experts, case studies, or standard-of-care",
        "answer": "C",
        "type": "text"
    },
    {
        "question": "Gout has been referred to as the 'disease of _____' and is more common in ___ countries such as ___, ___, _____ and in ___ adults > 80 yo",
        "answer": "Kings, developed, US, Japan, Australia, older",
        "type": "text"
    },
    {
        "question": "Risk factors/predisposing factors are ___ serum urate level >____ (___/___), o___, d____, s___ lifestyle, f___ history, m____ induced, r___ impairment, m___, a___",
        "answer": "Elevated, 6.8 mg/dL, obesity, dietary, sedentary, family, medication, renal, male, age",
        "type": "text"
    },
    {
        "question": "H____ does not always lead to gout and many patients with hyperuricemia remain a____",
        "answer": "Hyperuricemia, asymptomatic",
        "type": "text"
    },
    {
        "question": "Uric acid has no known physiologic purpose and is excreted in the g__ and k____",
        "answer": "Gut, kidney",
        "type": "text"
    },
    {
        "question": "Unlike other mammals, humans do not express the enzyme UA-> u___-->Allantoin",
        "answer": "Uricase",
        "type": "text"
    },
    {
        "question": "Differential diagnosis include: c___, s___ arthritis, s____ inflammatory arthritis, p____",
        "answer": "Cellulitis, septic, seronegative, pseudogout",
        "type": "text"
    },
    {
        "question": "Definitive diagnosis requires aspiration of s___ fluid from the affected joint and identification of intracellular crystals of m____ urate (MSU)",
        "answer": "Synovial, monosodium",
        "type": "text"
    },
    {
        "question": "Acute gouty arthritis is typically m____ and 50% of cases occurs on the 1st m______ joint aka “great toe or p____”",
        "answer": "Monoarticular, metatarsophalangeal joint, podagra",
        "type": "text"
    },
    {
        "question": "Onset of acute gouty arthritis is r___/s___ and intensity is e___ pain with i____",
		"answer": "Rapid/sudden, excruciating, inflammation",
        "type": "text"
    },
    {
        "question": "The term for redness is r___",
        "answer": "Rubor",
        "type": "text"
    },
    {
        "question": "The term for swelling is t__",
        "answer": "Tumor",
        "type": "text"
    },
    {
        "question": "The term for heat is c___",
        "answer": "Calor",
        "type": "text"
    },
    {
        "question": "The term for pain is d___",
        "answer": "Dolar",
        "type": "text"
    },
    {
        "question": "The term for loss of function is f____ l____",
        "answer": "Functio laesa",
        "type": "text"
    },
    {
        "question": "The pathophysiology is UA crystals are taken up by m____, m___ make i____ markers (ex. IL-1B), IL-1B helps recruit neutrophils into the a___ joint, activation and degranulation of n___ contribute to pain associated with acute gouty arthritis",
        "answer": "macrophages, macrophages, inflammatory, affected, neutrophils",
        "type": "text"
    },
    {
        "question": "The goal for treatment is t____ the acute attack ASAP",
        "answer": "Treatment",
        "type": "text"
    },
    {
        "question": "Non-pharmacologic therapy for acute gouty arthritis is local application of i___",
        "answer": "Ice",
        "type": "text"
    },
    {
        "question": "Pharmacologic therapy for acute gouty arthritis is m____ or c____ therapy depending on severity of pain and j____ involvement with N____, c___, and c____",
        "answer": "Monotherapy, combination, joint, NSAIDs, corticosteroids, colchicine",
        "type": "text"
    },
    {
        "question": "The brand name for indomethacin is _____ and the dosing range is ____mg T___",
        "answer": "Indocin, 50, TID",
        "type": "text"
    },
    {
        "question": "The generic name for Indocin is I_____ and the dosing range is ___ mg T____",
        "answer": "Indomethacin, 50, TID",
        "type": "text"
    },
    {
        "question": "The brand name for naproxen is n____ and the dosing range is ____ mg f/b ____ mg Q___hr",
        "answer": "Naprosyn, 750, 250, 8",
        "type": "text"
    },
    {
        "question": "The generic name for Naprosyn is n___ and the dosing range is ___ mg f/b ___mg Q_hr",
        "answer": "Naproxen, 750, 250, 8",
        "type": "text"
    },
    {
        "question": "The brand name for sulindac is c____ and the dosing range is ___ mg B___",
		"answer": "Clinoril, 200, BID",
        "type": "text"
    },
    {
        "question": "The generic name for clinoril is s____ and the dosing range is ___ mg B___",
        "answer": "Sulindac, 200, BID",
        "type": "text"
    },
    {
        "question": "The MOA of NSAIDs is r___ inhibition of c____ (COX-__ and COX-__) and inhibition of p___ synthesis",
        "answer": "Reversible, cyclooxygenase, 1, 2, prostaglandin",
        "type": "text"
    },
    {
        "question": "Adverse effects of NSAIDs is G___ bleeding (take with f___), edema, i___ bleeding, r___ impairment, increased risk of c___ and t___ events with long term use",
        "answer": "GI, food, increased, renal, cardiovascular, thromboembolic",
        "type": "text"
    },
    {
        "question": "There is higher chance of stomach bleeding if you are >____yo, have > 3 alcoholic drinks/day with concomitant NSAIDs use, taking other N____, taking blood t___ or systemic steroid drugs, history of stomach u___ or bleeding problems, taking m___ or for a longer time than directed",
        "answer": "60, NSAIDs, thinners, ulcers, more",
        "type": "text"
	},
    {
        "question": "The MOA of corticosteroids is to r__ the expression of p__-inflammatory genes via activation of the glucocorticoid receptor, r__ the expression of p___-inflammatory transcription factors through transrepression, i__ the synthesis of a___-inflammatory proteins",
        "answer": "Reduce, pro, reduce, pro, increase, anti",
        "type": "text"
    },
    {
        "question": "Adverse effects of corticosteroids are C__(C___ syndrome), U__, S__ marks, s___ thinning, H__,h___, i___ BP, I__, i__, N__ of femoral heads, G___ elevation, G_ upset, DM, O___, o__, I___ wound healing, i___, D___/m__ changes",
        "answer": "Cataracts, cushing, ulcers, stretch, skin, hypertension, hirsutism, increased, immunosuppression, infection, necrosis, glucose, GI, osteoporosis, obesity, impaired, insomnia, depression,/mood",
        "type": "text"
    },
    {
        "question": "Short term corticosteroid effects are i___BP, g___ elevation, G___ upset, I___, m__ changes",
        "answer": "Increased, glucose, GI, insomnia, mood",
        "type": "text"
    },
    {
        "question": "Patient counseling points for corticosteroids include: s___ upset, take with f__, i___, take in the morning, increase in blood sugar, m___ blood sugar, increased f__ retention, increase in b__ pressure, monitor",
        "answer": "Stomach, food, insomnia, monitor, fluid, blood",
        "type": "text"
    },
    {
        "question": "Colchicine MOA i___ phagocytosis of UA crystals, interferes with i___ complex and inhibits IL-1 a___, inhibits neutrophil m______, a___, and d___",
        "answer": "Inhibits, inflammasome, activation, migration, activation, degranulation",
        "type": "text"
    },
    {
        "question": "Colchicine is dosed at __ mg followed by ___ mg ___ hour later and clearance is d___ in s__ renal and hepatic impairment and has DDI with C___ and P___ inhibitors",
        "answer": "1.2, 0.6, 1, decreased, severe, CYP3A4, p-glycoprotein",
        "type": "text"
    },
    {
        "question": "Adverse effects of colchicine include d__, n___, v___, m___",
        "answer": "Diarrhea, nausea, vomiting, myelosuppression",
        "type": "text"
    },
    {
        "question": "Counseling for Colchicine is to s__ therapy within __ hours of symptom onset, do not use if you have been using colchicine for treatment of acute gout attack in the last __ days",
        "answer": "Start, 36, 14",
        "type": "text"
    },
    {
        "question": "Cochicine prophylaxis dose can be restarted (0.6 mg daily or BID) ___ hours after treating an acute attack with colchicine treatment dose (1.2 mg followed by 0.6 mg)",
        "answer": "12",
        "type": "text"
    },
    {
        "question": "Colchicine is not an analgesic and should not be used to treat pain from other causes and can be used for both a__ attack and p___ but at d__ doses",
        "answer": "Acute, prophylaxis, different",
        "type": "text"
    },
    {
        "question": "Monotherapy for mild-moderate attack of gout affecting 1 or few small joints or 1-2 large joints is e__ effective and the most appropriate therapy should be chosen based on patient’s preference, p__ response, and associated c___",
		"answer": "Equally, prior, comorbidities",
        "type": "text"
    },
    {
        "question": "Combination therapy for severe or refractory attack involving 1-2 large joints or polyarticular is s___ use of full doses of c__ + N__, c___ + oral c____, intra-articular s__ + c__/N___/oral c___",
        "answer": "Simultaneous, colchicine, NSAIDs, colchicine, corticosteroids, steroids, colchicine/NSAIDs/corticosteroids",
        "type": "text"
    },
    {
        "question": "The treatment plan goal for hyperuricemia is to p___ recurrent gout attacks by maintaining low uric acid levels (<__ mg/dL or sometimes <__ mg/dL)",
        "answer": "Prevent, 6, 5",
        "type": "text"
    },
    {
        "question": "Non-pharmacologic therapy for hyperuricemia is w___ loss, e___, reduce a__ intake, limit consumption of high-fructose corn syrup and p___ rich foods (organ m__, s__)",
        "answer": "Weight, exercise, alcohol, purine, meats, seafood",
        "type": "text"
    },
    {
        "question": "Pharmacologic therapy for hyperuricemia is d___ unnecessary medications that increase U__ levels, and u__ lowering therapy",
        "answer": "Discontinue, UA, urate",
        "type": "text"
    },
    {
        "question": "Purine rich food with ___-___ mg/100g is b__, l___, k___, g___, t___, v___, t__, p___",
        "answer": "75-100, bacon, liver, kidneys, goose, turkey, veal, trout, pigeon",
        "type": "text"
    },
    {
        "question": "Purine rich food with >___mg/100g is h__, meat extracts, m__, s___, s___, s___, y__",
        "answer": "100, herring, mussels, sardines, smelts, sweetbreads, yeast",
        "type": "text"
    },
    {
        "question": "Medications that worsen gout are d___ such as t__, l___, n___, s___, l___, e__, e___, p___, c___",
        "answer": "Diuretics, thiazide, loop, niacin, salicylates, levodopa, ethanol, ethambutol, pyrazinamide, cyclosporine",
        "type": "text"
    },
    {
        "question": "Criteria for Urate lowering therapy are for: patients with > _ gouty attacks per year (evidence _), presence of one or more t__ (Evidence _), c___ kidney disease (stage _ or worse (Evidence _), history of u___ (Evidence _)",
        "answer": "2, A, tophus, A, chronic, 2, C, urolithiasis, C",
        "type": "text"
    },
    {
        "question": "MOA of xanthine oxidase inhibitors is it b___ formation of u___ acid and d__ serum UA levels and it is a _ line therapy",
        "answer": "Blocks, uric, decreases, 1st",
        "type": "text"
    },
    {
        "question": "Hypoxanthine blocks xanthine formation by a___ and f__and xanthine blocks uric acid formation by a___ and f___",
        "answer": "Allopurinol, febuxostat, allopurinol, febuxostat",
        "type": "text"
    },
    {
        "question": "Initial dosing for allopurinol is ___-___ mg daily (__ mg in CKD stage _), and titrate up every __-___ weeks until UA target reached and maximum dose is ___ mg/day (in divided doses)",
        "answer": "50-100, 50, 4, 800",
        "type": "text"
    },
    {
        "question": "Allopurinol warnings include h___ reaction/s___ rash, S___ J___ S___ (SJS), and genetic testing for H____ prior to starting therapy in K___ with CKD stage > _, Han C___ or T___ irrespective of renal function",
        "answer": "Hypersensitivity, severe, Steven Johnson Syndrome, HLA-B*5801, Koreans, 4, Chinese, Thai",
        "type": "text"
    },
    {
        "question": "Side effects of allopurinol include r__, increased L___, a__ g__ attacks, and this can be prevented by using c___ or N___ for up to __ months c___ to reduce the risk of acute attacks when starting u__ lowering therapy",
        "answer": "Rash, LFTs, acute gout, colchicine, NSAIDs, 6, concurrently, urate",
        "type": "text"
    },
    {
        "question": "Febuxostat (Uloric) is dosed at __-___ mg daily and has warnings for h__, h___ (less than allopurinol), t___ events and has contraindications with a___ or m___",
        "answer": "40-80, hepatotoxicity, hypersensitivity, thromboembolic, azathioprine, mercaptopurine",
        "type": "text"
    },
    {
        "question": "Side effects of febuxostat (Uloric) is r__(less than allopurinol), increased L___ (d/c if LFTs > __x ULN), and this can be prevented by using c___ or N___ for up to __ months c___ to reduce the risk of acute attacks when starting u__ lowering therapy",
        "answer": "Rash, LFTs, 3, colchicine, NSAIDs, 6, concurrently",
        "type": "text"
    },
    {
        "question": "Lesinurad (Zurampic) MOA of U___ acid transporter1 (URAT1) inhibitor is i___ the function of transporter proteins involved in uric acid r___, d__ serum uric acid level, i___ renal clearance, and fractional absorption of uric acid",
        "answer": "Uric, inhibits, reabsorption, decreased, increased",
        "type": "text"
    },
    {
        "question": "Lesinurad + allopurinol is D___",
        "answer": "Duzallo",
        "type": "text"
    },
    {
        "question": "Lesinurad (Zurampic) is not used as m___ and should be used in combination with X___, and there is a black box warning for a___ r___ f___ (especially when used a__), and contraindication is CrCl <___mL/min, E__, K__ transplant, d___",
        "answer": "Monotherapy, XOI, acute renal failure, alone, 30, ESRD, kidney, dialysis",
        "type": "text"
    },
    {
        "question": "Patient counseling for Lesinurad is to stay well h___ (~__L/day), ___ mg PO Q__ with a dose of X__, decrease efficacy of oral c___ ",
        "answer": "Hydrated, 2, AM, XOI, contraceptives",
        "type": "text"
    },
    {
        "question": "Adverse effects of lesinurad (Zurampic) is c___ effects, g__ flares (recommend gout flare p__), n___, h___, i___, G____ and metabolism is through___ where poor metabolizers have __x higher drug exposure",
        "answer": "Cardiovascular, gout, prophylaxis, nephrotoxicity, headache, influenza, GERD, CYP2C9, 1.8",
        "type": "text"
    },
    {
        "question": "MOA of uricosuric agents is i___ renal excretion of U__ by inhibiting proximal tubular r___ and is an a__ 1st line",
        "answer": "increased, UA, reabsorption, alternative",
        "type": "text"
    },
    {
        "question": "Probenacid (Probalan) is useful in urate u___, and is dosed initially at ___ mg B___ for __ week and is titrated up to ___-___ mg/day until target UA and has a warning of i__ risk of hemolytic anemia in patients with G__ deficiency",
        "answer": "underexcretion, 250, BID, 1, 500-2000, G6PD",
        "type": "text"
    },
    {
        "question": "Probenacid (Probalan) is not recommended as m___ in patients with CrCl<___ mL/min or history of u___ and should avoid use in patients with CrCl <___mL/min",
        "answer": "monotherapy, 50, 30",
        "type": "text"
    },
    {
        "question": "Contraindications for Probenacid (Probalan) are concomitant use of A__ (>___mg), u___, initiation during a__ g___ a__, blood d___ and side effects include h___ reactionis, h___ anemia, and a__g___ a__",
        "answer": "ASA, 325, urolithiasis, acute gout attack, dyscrasias, hypersensitivity, hemolytic, acute gout attacks",
        "type": "text"
    },
    {
        "question": "The MOA for urate oxidase enzyme is p___ recombinant uricase and converts UA to a___ (water solube and easily excreted through kidneys)",
        "answer": "pegylated, allantoin",
        "type": "text"
    },
    {
        "question": "Pegloticase (Krystexxa) is used for s__ r__ g___ and is dosed at __ mg IV infusion Q_wks (over at least _ hours), and there is a risk of a___ (infusion related reactions) and patient should be pre-medicated with a__ and c___",
        "answer": "severe, refractory gout, 8, 2, anaphylaxis, antihistamine, corticosteroids",
        "type": "text"
    },
    {
        "question": "Pegloticase (Krystexxa) should be discontinued or oral a___ agents should not be initiated prior to initiating Pegloticase",
        "answer": "antihyperuricemic",
        "type": "text"
    },
    {
        "question": "Pegloticase (Krystexxa) needs to be protected from l__, r___ vials, do not s____, and must be used within _ hours after dilution",
        "answer": "light, refrigerate, shake, 4",
        "type": "text"
    },
    {
        "question": "Pegloticase (Krystexxa) contraindication occurs for patients with G___ deficiency and has warnings for h___/a___, may exacerbate C___, i___, and a__g__a___ and this can be prevented by using c__ daily or N___ before and after (up to 6 months) concurrently to reduce the risk of acute attacks",
        "answer": "G6PD, hypersensitivity/anaphylaxis, CHF, immunogenicitiy, acute gout attacks",
        "type": "text"
    },
    {
        "question": "L___(Cozaar) is useful as anti-___ and u__ effects and F____ (Tricor)",
        "answer": "losartan, hypertension, uricosuric, fenofibrates",
        "type": "text"
    },
    {
        "question": "The goal for monotherapy is to reduce UA to <__mg/dL (sometime <_mg/dL), a__ or f___ is __ line therapy and p__ is an alternative 1st line treatment if x___ oxidase inhibitors contraindicated/not tolerated",
        "answer": "6, 5, allopurinol, febuxostat",
        "type": "text"
    },
    {
        "question": "If the serum UA levle is still not at goal maximize X__ dose and/or do c___ therapy of X___ + p___ OR X___ + U___ OR add other u___ agents such as l___ or f___ and last resort is p___",
        "answer": "XOI, combination, XOI, probenacid, XOI, URAT1, uricosuric, losartan, fenofibrates, pegloticase",
        "type": "text"
    },
    {
        "question": "Initiating urate lowering therapy in patients can cause an a__ g__ a___ and this affects patient c___ and long term effects include u__ a__ n___, g__ n___, t___ g__, and ways to increase compliance would be to c___ initiate acute gout p__ with urate lowering therapy and start acute gout prophylaxis prior to initiating urate lowering therapy",
        "answer": "acute gouty attack, compliance, urice acid nephrolithiasis, gouty nephropathy, tophaceous gout, prophylaxis",
        "type": "text"
    },
    {
        "question": "Goal of acute gout prophylaxis is to i__ patient c___ with urate lowering therapy and p__ acute gouty arthritis attack",
        "answer": "increase, compliance, prevent",
        "type": "text"
    },
    {
        "question": "Pharmacologic therapy for acute gout prophylaxis is to use c__ as __ line therapy and low dose N___ and low dose oral c___",
        "answer": "colchicine, 1st, NSAIDs, corticosteroids",
        "type": "text"
    },
    {
        "question": "Colchicine is dosed at __ mg daily or twice daily and dose is adjusted in s__ renal impairment and/or concomitant use with C__/P__ inhibitor",
        "answer": "0.6, severe, CYP3A4/Pgp",
        "type": "text"
    },
    {
        "question": "Low dose Naproxen is dosed at __ mg PO B__ and P__ or H___ may be considered if needed",
        "answer": "250, BID, PPIs, H2-blockers",
        "type": "text"
    },
    {
        "question": "Low dose oral c___ is used only if colchicine/NSAIDs are c___/not t___/i___ such as p___/p__,__ mg/day",
        "answer": "corticosteroids, contraindicated, tolerated, ineffective, prednisone/prednisolone, 10",
        "type": "text"
    }
]
